Table 1 Baseline characteristics of the study patients
Variables | Probiotic group (n = 17) | Placebo group (n = 18) | p |
|---|---|---|---|
Age | 38.64 ± 9.12 | 38.61 ± 11.92 | 0.6 |
sex (%) | 17 | 18 | 0.12 |
Male | 8 (47.1) | 13 (72.2) | |
Female | 9 (52.9) | 5(27.8) | |
Asthma family history (%) | 0.40 | ||
Negative | 8 (47.1) | 6 (33.3) | |
Positive | 9 (52.9) | 12 (66.7) | |
Flow-up, mean (S.D.), days | 80.4 ± 23.3 | 66.4 ± 17.9 | 0.14 |
BMIa, mean (S.D.), Kg/m2 | 25.9 ± 4.2 | 26.8 ± 2.7 | 0.10 |
Exposure to tobacco smoking (%) | 0.35 | ||
Negative | 12 (70.6) | 10 (55.6) | |
Positive | 5 (29.4) | 8 (44.4) | |
Caesarean delivery (%) | 0.13 | ||
Natural | 10 (58.8) | 6 (33.3) | |
Caesarean | 7 (41.2) | 12 (66.7) | |
Pets at home (%) | 0.95 | ||
Have pet | 2 (11.8) | 2 (11.1) | |
Not having pet | 15 (88.2) | 16 (88.9) | |
Influenza vaccine (%) | 0.92 | ||
Negative | 13 (76.5) | 14 (77.8) | |
Positive | 4 (23.5) | 4 (22.2) | |
Covid-19 in the intervention period (%) | 0.29 | ||
Negative | 17 (100) | 18 (100) | |
Positive | 0 (0) | 0 (0) | |
Medicationsb | 0.73 | ||
Beclomethasone + albuterol | 9 (52.9) | 8 (47.1) | |
Fluticasone + albuterol | 8 (44.4) | 10 (55.6) |